<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036854</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-P8-690</org_study_id>
    <nct_id>NCT01036854</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)</brief_title>
  <official_title>Parallel, Group, Laboratory-Blinded, Single and Multiple-dose Pharmacokinetic Study of Ondansetron Administered as the Immediate-Release (Zofran) and Modified-Release (EUR1025) Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess blood levels of ondansetron (EUR1025 24 mg) dose and
      Zofran 8 mg dose after single and multiple doses are given when taken with a meal and taken
      on an empty stomach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetics (PK) of ondansetron
      administered as a novel modified-release formulation (EUR1025 24 mg) as well as the
      immediate-release formulation (Zofran 8 mg) after single and multiple oral dose
      administration under fasting and fed conditions based on the requirements of the respective
      indications. The safety profile of each treatment will also be assessed by recording the
      nature, severity, frequency, duration and relation to the treatment of any adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ondansetron plasma concentrations will be measured by using a validated HPLC/MS assay.</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Regime 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regime 1 will be orally administered once daily in the morning over 6 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regime 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regime 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regime 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 &amp; 5- two placebo capsules on each day; Day 6- a single does will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1025</intervention_name>
    <description>orally, 24 mg, daily for 6 days</description>
    <arm_group_label>Regime 1</arm_group_label>
    <other_name>Ondansetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1025</intervention_name>
    <description>orally, 8 mg, twice daily over 6 consecutive days</description>
    <arm_group_label>Regime 2</arm_group_label>
    <other_name>Ondansetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1025</intervention_name>
    <description>orally, 8 mg, three times a day over 6 consecutive days</description>
    <arm_group_label>Regime 3</arm_group_label>
    <other_name>Ondansetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1025</intervention_name>
    <description>orally, 8 mg, 16 mg, 24 mg, daily, for 6 days</description>
    <arm_group_label>Regime 4</arm_group_label>
    <other_name>Ondansetron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers

          -  Non- or ex-smokers

          -  At least 21 years of age but not older than 55 years

          -  Body mass index targeted to be at least 18.5 and less than 30 kg/m2.

          -  Acceptable lab tests

          -  Normal 12 lead ECG

          -  Negative human chorionic gonadotropin (hCG) for females.

        Exclusion Criteria:

          -  No known hypersensitivity to Ondansetron or any related products

          -  No presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption

          -  No presence of significant heart disease or disorder discovered on screening ECG

          -  Not pregnant

          -  No alcohol or drug abuse history

          -  No use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP)

          -  No previous Investigational Product (in another clinical trial) or donated 50 ml or
             more of blood in the previous 28 days before day 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma INc.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3PI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ondansetron, EUR-1025</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

